Clinical Trial: Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
Brief Summary: This trial will investigate the combination of bevacizumab, and erlotinib in patients with adenocarcinoma or poorly differentiated carcinoma of unknown primary site. Bevacizumab and erlotinib are relatively well-tolerated and have non-overlapping toxicity profiles. This trial will be one of the first clinical trials to evaluate a combination of targeted agents in the treatment of a solid tumor.
Detailed Summary:
Upon determination of eligibility, patients will be receive:
- Bevacizumab + Erlotinib
Sponsor: SCRI Development Innovations, LLC
Current Primary Outcome: Overall response rate
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Time to progression
- Overall survival
- Overall tolerability
- Overall toxicity
Original Secondary Outcome: Same as current
Information By: SCRI Development Innovations, LLC
Dates:
Date Received: September 12, 2005
Date Started: April 2004
Date Completion:
Last Updated: September 15, 2010
Last Verified: September 2010